• Home
  • About Us
  • Resource Library
Select the search type
 
  • Site
Search
Global Polio Eradication Initiative
  • Polio and prevention
  • Infected countries
  • Data and monitoring
  • Post-eradication
  • Research
  • Financing
  • Media room
You are here: Research > Polio Pipeline > No.5 Winter 2010 > Global status of licensure
print this page
  • OPV efficacy
  • OPV delivery
  • Affordable IPV
  • Vaccine-derived polioviruses
  • Frequently asked questions
  • Polio Pipeline
    • No.8 Summer 2011
    • No.7 Winter 2011
    • No.6 Summer 2010
    • No.5 Winter 2010
      • Polio Research
      • Conclusions and recommendations
      • Research area 1
      • Research area 2
      • Delivering monovalent OPV
      • Independent evaluation calls for more research to
      • Global status of licensure
      • The use of LQAS
      • Where are the immunity gaps?
    • No.4 Summer 2009
    • No.3 Winter 2009
    • No 2, Autumn 2008
    • No.1 Summer 2008
  • Polio Research Committee
  • Grants and collaboration
  • Antivirals
  

Global status of licensure and pre-qualification processes for monovalent OPV type 1, 2 and 3 and bivalent OPV

Monovalent OPV type 1 (mOPV1)


Monovalent OPV type 3 (mOPV3)


Bivalent OPV containing type 1 and 3 (bOPV1&3)



* SAS: special access scheme for specific use
** The letter sent to UNICEF recommends the procurement of the product
*** Completion of the prequalification process depends on satisfactory outcome of ongoing clinical trials

  • oral polio vaccine, 
  • OPV, 
  • research news article, 
  • monovalent oral polio vaccine, 
  • mOPV, 
  • bivalent oral polio vaccine, 
  • bOPV

The Global Polio Eradication Initiative © Copyright 2010

  • Site map
  • |
  • Vacancies
  • |
  • Acronyms
  • |
  • Contact us
  • |
  • Terms of use
  • |
  • Login